Sold as Uniretic. Every FDA application for this active ingredient: 1 branded and 4 generic. Boxed warning
As of Nov 22, 2026, FDA lists 5 applications for Hydrochlorothiazide; Moexipril hydrochloride (sold as Uniretic), first approved Jun 27, 1997, with 0 new uses approved and 0 published complete response letters.
| Jun 27, 1997 | UnireticNDA 20729 · New combination | UCB | 16 | Discontinued |
| Mar 7, 2007 | Moexipril Hydrochloride and HydrochlorothiazideANDA 76980 | Teva Pharmaceutical Industries | 6 | Marketed |
| Sep 25, 2008 | Moexipril Hydrochloride and HydrochlorothiazideANDA 90096 | Chartwell RX | 2 | Discontinued |
| Mar 17, 2010 | Moexipril Hydrochloride and HydrochlorothiazideANDA 90718 | Glenmark Pharmaceuticals | 5 | Discontinued |
| Mar 7, 2014 | Moexipril Hydrochloride and HydrochlorothiazideANDA 202150 | Heritage Pharmaceuticals | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA